Toxic epidermal necrolysis syndrome (TENS) is a rare, life-threatening medical emergency typically associated with recent drug exposure. Although several theories exist, recent insight has implicated the innate immune system as a significant contributor to the initiation and propagation of this devastating reaction. Standard therapies including transfer to specialized burn units, nutritional support, and protection from infection, remain the mainstay in the treatment of TENS. While alternative treatment strategies have been pursued and reported, there remains no published data that convincingly supports these further interventions. Given the rare nature of this syndrome, multi-institutional studies will be necessary and essential in improving the understanding and treatment of TENS.

Download full-text PDF

Source
http://dx.doi.org/10.1097/BCR.0b013e31815f3658DOI Listing

Publication Analysis

Top Keywords

treatment strategies
8
toxic epidermal
8
epidermal necrolysis
8
necrolysis syndrome
8
treatment tens
8
treatment
4
strategies toxic
4
syndrome at?
4
at? toxic
4
syndrome tens
4

Similar Publications

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, extracellular amyloid-β (Aβ) plaque accumulation, and intracellular neurofibrillary tangles. Recent efforts to find effective therapies have increased interest in natural compounds with multifaceted effects on AD pathology. This study explores natural compounds for their potential to mitigate AD pathology using molecular docking, ADME screening, and assays, with ruscogenin─a steroidal sapogenin from emerging as a promising candidate.

View Article and Find Full Text PDF

Background: Due to advances in treatment, HIV is now a chronic condition with near-normal life expectancy. However, people with HIV continue to have a higher burden of mental and physical health conditions and are impacted by wider socioeconomic issues. Positive Voices is a nationally representative series of surveys of people with HIV in the United Kingdom.

View Article and Find Full Text PDF

Objective: Cervical spondylotic myelopathy (CSM) shows varying levels of improvement after surgical treatment. While some patients improve soon after surgery, others may take months to years to show any signs of improvement. The goal of this study was to evaluate postoperative improvement, patient-reported outcomes, and patient satisfaction up to 2 years after surgical treatment for CSM, which will help optimize the current treatment strategies and effectively manage patient expectations.

View Article and Find Full Text PDF

Bridging thrombolysis versus direct endovascular treatment in acute vertebrobasilar artery complex occlusion.

J Neurosurg

January 2025

1Department of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui.

Objective: Endovascular treatment (EVT) is an effective treatment for patients with acute vertebrobasilar artery complex occlusion (VBAO). However, the benefit of bridging thrombolysis prior to EVT remains controversial. The purpose of the present study is to explore the best treatment strategy between bridging treatment (BT) and direct EVT in patients with acute VBAO.

View Article and Find Full Text PDF

Objectives: This study introduces Smart Imitator (SI), a 2-phase reinforcement learning (RL) solution enhancing personalized treatment policies in healthcare, addressing challenges from imperfect clinician data and complex environments.

Materials And Methods: Smart Imitator's first phase uses adversarial cooperative imitation learning with a novel sample selection schema to categorize clinician policies from optimal to nonoptimal. The second phase creates a parameterized reward function to guide the learning of superior treatment policies through RL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!